Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02447939
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
- Conditions
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 135
- Registration Number
- NCT02439411
- Locations
- 🇪🇸
Hospital Universitario Son Espases, Palma De Mallorca, Baleares, Spain
🇪🇸Hospital Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Instituto Catalán de Oncología Badalona/Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 16
- Registration Number
- NCT02428270
- Locations
- 🇨🇦
Juravinski Cancer Center, Hamilton, Ontario, Canada
🇨🇦London Regional Cancer Centre, London, Ontario, Canada
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
- Conditions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02416232
- Locations
- 🇫🇷
GSK Investigational Site, Villejuif cedex, France
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Prof. Dr. med. Dirk Schadendorf
- Target Recruit Count
- 10
- Registration Number
- NCT02410863
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, BW, Germany
🇩🇪National Centre for Tumour Diseases (NCT), Heidelberg, BW, Germany
🇩🇪Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden, Saxony, Germany
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 14
- Registration Number
- NCT02399943
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT02367859
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT02357732
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Conditions
- Interventions
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02314143
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.